September 20 - 23, 2014
Sheraton Philadelphia Downtown
Philadelphia, Pa., USA
Abstract submission deadline: Friday, August 8
Advance registration deadline: Monday, August 4
Continental Breakfast7:00 a.m.-8:00 a.m.
Plenary Session 1: Tumor Microenvironment and MetabolismSession Chairperson: Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Mass.*Please note: Dr. John Gribben is unable to attend.8:00 a.m.-10:00 a.m.
Mouse models of isocitrate
dehydrogenase (IDH) mutations in hematologic malignanciesTak W. Mak, Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, Ont., Canada
Patient AdvocateJack Whelan, Jack-Whelan.com
Multiple myeloma as a model of bone metastasisIrene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Mass.
The microenvironment in CLL: Cellular and molecular players and emerging therapeutic targetsJan A. Burger, The University of Texas MD Anderson Cancer Center, Houston, Texas
Break10:00 a.m.-10:30 a.m.
Plenary Session 2: ImmunotherapySession Chairperson: Ronald Levy, Stanford University, Stanford, Calif.10:30 a.m.-12:30 p.m.
CARs for leukemia and beyond?Carl H. June, Abramson Cancer Center of University of Pennsylvania, Philadelphia, Pa.
Monoclonal antibodies and in situ vaccinationRonald Levy
Developing broadly active immunotherapyGlenn Dranoff, Dana-Farber Cancer Institute, Boston, Mass.
Pre-clinical development of a humanized anti-CD47 antibody targeting AML stem cells Ravindra Majeti, Stanford School of Medicine, Stanford, Calif.
Lunch12:30 p.m.-1:00 p.m.
Panel Discussion 1: Drug Development in the 21st Century: Tackling the Grand Challenges1:00 p.m.-2:30 p.m.Session Chairperson: Wyndham E. Wilson, National Cancer Institute, Bethesda, Md.
PanelistsWyndham H. Wilson
Richard B. Gaynor, Eli Lilly and Company, Indianapolis, Ind.
Michael J. Keating, The University of Texas MD Anderson Cancer Center, Houston, Texas
James L. Omel, Central Nebraska Multiple Myeloma Support Group, Grand Island, Neb.
Poster Session A with Light Refreshments2:30 p.m.-5:00 p.m.
Joint Session with AACR Melanoma Special Conference:Clinical Science Intersections between Melanoma and Hematologic Malignancies5:00 p.m.-7:30 p.m.Two hematology experts will be joined by two speakers from the AACR Special Conference on Advances in Melanoma: From Biology to Therapy to create a unique session and an opportunity to interact with colleagues across disciplines. Overlapping themes in solid and blood cancers will be discussed in the areas of signaling, targeted therapy, and immunotherapy. Introduction by Session ChairpersonsKenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Mass.Levi A. Garraway, Dana-Farber Cancer Institute, Boston, Mass.
MRA: Powerful research, Faster resultsWendy K.D. Selig, President and CEO, Melanoma Research Alliance, Washington, D.C.
Research: Moving beyond hope to outcomesElizabeth Thompson, CEO, Lymphoma Research Foundation, New York, N.Y.
Preclinical models for targeting oncogenic Ras signaling in cancerKevin M. Shannon, University of California, San Francisco, Calif.
Treatment of non-V600- mutated BRAF melanoma: A role for combination MEK and CDK4/6 inhibitionJeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, Tenn.
PD-1 pathway immunotherapy Gordon Freeman, Dana-Farber Cancer Institute, Boston, Mass.
Adoptive T-cell therapy with CAR-modified T-cells: We have a Model A Ford—can we build a Ferrari?Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, N.Y.
Reception for the attendees of both AACR Special Conferences7:30 p.m.-9:00 p.m.